PPBT PURPLE BIOTECH LTD. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1614744 · Fiscal year ends 12/31
Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $3.73M | $7.62M | $17.03M | $16.32M | $11.83M |
| SG&A expense | $3.25M | $3.18M | $5.24M | $6.28M | $6.11M |
| Operating income | — | — | -$22.27M | -$22.60M | -$17.93M |
| Interest expense | $982,000 | $483,000 | $2.19M | $67,000 | -$212,000 |
| Net income | -$26.39M | -$7.24M | -$19.88M | -$21.67M | $18.38M |
| EPS (basic) | 0.03 | 4.44 | 17.96 | 23.97 | 17,568,036.00 |
| EPS (diluted) | 0.03 | 4.99 | 17.96 | 23.97 | 17,568,036.00 |
| Weighted avg. shares (diluted) | 480,053 | 1.64M | 1.11M | 904,054 | — |
| Balance sheet | |||||
| Cash & equivalents | $8.72M | $7.40M | $14.49M | $15.03M | $10.89M |
| Short-term investments | — | $275,000 | $73,000 | $431,000 | $36.31M |
| Receivables | — | — | — | $431,000 | — |
| Current assets | $9.87M | $8.91M | $15.79M | $33.26M | $48.47M |
| PP&E, netmay include right-of-use assets (IFRS) | $124,000 | $124,000 | $154,000 | $215,000 | $277,000 |
| Intangibles | $7.36M | $27.84M | $28.04M | $20.68M | $20.48M |
| Total assets | $17.57M | $37.04M | $44.30M | $54.62M | $70.20M |
| Current liabilities | $7.75M | $3.99M | $9.70M | $7.06M | $4.25M |
| Total liabilities | $7.91M | $4.13M | $10.01M | $7.52M | $5.09M |
| Shareholders' equity | $9.71M | $32.86M | $34.21M | $46.91M | $64.83M |
| Cash flow statement | |||||
| Operating cash flow | -$5.66M | -$14.37M | -$19.93M | -$16.73M | -$374,000 |
| Capital expenditure | $3,000 | — | $3,000 | $26,000 | $115,000 |
| Free cash flow | -$5.66M | — | -$19.93M | -$16.76M | -$489,000 |
| Investing cash flow | $632,000 | $509,000 | $13.88M | $19.91M | $13.41M |
| Financing cash flow | $6.33M | $6.77M | $5.45M | $1.11M | — |
| Stock-based compensation | $309,000 | $582,000 | $1.88M | $2.41M | $2.08M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.